Sample
Serum, Plasma, (citrate, heparin)
Intended Use
Human measles IgG ELISA kit is intended for analysing in-vitro qualitative levels of human IgG antibodies against measles virus (measles-IgG) in plasma or serum (citrate, heparin).
Storage
Store at 2 - 8°C. Do not use the kit beyond the expiration date.
Performance Characteristics
The diagnostic specificity is defined as the probability of the assay of scoring negative in the absence of the specific anal yte. It is 100% (95% confidence interval: 90.0% - 100%).
The diagnostic sensitivity is defined as the probability of the assay of scoring positive in the presence of the specific analyte. It is 97.01% (95% confidence interval: 93.93% - 98.79%).
General Description
Measles (also called rubeola), is an extremely contagious viral disease which can be transmitted by respiratory secretions. The measles virus is a negative sense, single stranded enveloped RNA virus that belongs to the Morbillivrus (Paramyxovirdae family). The virus is able to infect cells in the lungs and those that are at the back of the throat, causing symptoms such as sore throat, dry cough, a runny nose, tiny white spots inside the mouth, a high fever, red eyes and a characteristic rash. Two of the most common methods which are used for detecting measles infection are: antibody testing (IgG and IgM) and viral islation detection (RT-PCR).
Citations
Publication ()
Have you cited DEIA359 in a publication?
Let us know and earn a reward for your research.
Comparison of measles plaque reduction neutralization test (PRNT) and measles virus-specific IgG ELISA for assessment of immunogenicity of measles-mumps-rubella vaccination at 5-7 months of age and maternal measles antibodies
Vittrup DM, Jensen A, Malon M, Zimakoff AC, Kiehn Sørensen J, Littell B, Simões EAF, Svensson J, Graff Stensballe L
Applications: ELISA
Reactive species: Human
"Abstract: Background:Assessing the risk of measles outbreaks and identifying the susceptible parts of the population is essential to timely intervention. Infants between 6-12 months are increasingly susceptible to measles but evaluating the performance of high throughput enzyme immunoassays (ELISAs) in infants < 9 months of age is lacking.
Methods:A commercially available ELISA kit (Creative Diagnostics, DEIA359) for estimating measles seroprotection was evaluated in infants 5-7 months of age. In an immunogenicity substudy in the Danish MMR trial conducted between 2019-2021, infants (and mothers at baseline) were sampled before and one month after measles-mumps-rubella vaccination (MMR) or placebo as well as one month after routine MMR at 15 months. Measles IgG ELISA was compared to the gold standard but labor-intensive measles plaque reduction neutralization test (PRNT) by Pearson and Spearman correlations and by estimating sensitivity, specificity, and positive and negative predictive values (PPV and NPV).
Findings:Measles IgG levels compared to PRNT antibodies had a Pearson's correlation coefficient between 0.10-0.24. Seroprotection rates measured by ELISA in young infants were 10-14% lower than measured by PRNT. The sensitivity of the ELISA to detect serological protection compared to PRNT in the infant population differed markedly across sampling time points and was 14%, 40%, and 92% at baseline, post-intervention, and post-routine MMR, whereas the specificity was 99%, 93%, and 43%, respectively. The PPV and NPV were 68% and 87% in infants at baseline."
Article snippet: A commercially available ELISA kit (Creative Diagnostics, DEIA359) for estimating measles seroprotection was evaluated in infants 5–7 months of age. 
Figure 1. Measurement of measles neutralizing antibodies by PRNT plotted against measurements of measles IgG by ELISA.
Measles-mumps-rubella-vaccination at 6 months of age induces measles-specific T cell responses: a randomized controlled trial
Buus S, Vittrup DM, Schmidt JD, Jensen A, Stryhn A, Stensballe LG.
Applications: ELISpot
Reactive species: Human
"Abstract: Background
Measles is a highly contagious viral disease, particularly severe in infants. Protection in early life is provided by maternally transferred antibodies, but this period is shorter in infants of previously vaccinated mothers (PVMs) compared to infants of previously measles-infected mothers (PIMs). Earlier measles-mumps-rubella (MMR) vaccination may compensate for this. To evaluate immune responses, 6-month-old infants were randomized to receive early MMR or placebo. This study reports the cellular immune outcomes and summarizes serological and T-cell responses.
Methods
A double-blind, randomized trial involved 6540 Danish infants aged 5–7 months, eligible if birth weight exceeded 1000 grams and gestational age was ≥32 weeks. Participants were randomized 1:1 to receive M-M-RVaxPro or placebo. Blood samples were collected before intervention, four weeks after intervention, and four weeks after routine MMR at 15 months. Peripheral blood mononuclear cells (PBMCs) were prepared, and an IFN-γ specific ELISpot assay measured measles-specific T cells.
Results
Among 750 infants (341 MMR, 409 placebo) in the cellular immunogenicity trial, a significant cellular immune response was observed one-month post-intervention in the MMR group compared to placebo (geometric mean ratio [GMR]: 12.3; 95% CI: 6.9–21.9). The cellular conversion rate (CCR) in the MMR group was 45%, comparable to the previously reported seroconversion rate. However, following routine MMR at 15 months, a reduced cellular response was observed in the early MMR group (GMR: 0.6; 95% CI: 0.3–0.9). Post-routine MMR, CCRs were 66% (MMR) and 74% (placebo). The immune conversion rate (ICR, defined as seroconversion and/or T-cell response) reached 99% in both groups post-routine MMR.
Conclusion
Early MMR at 6 months elicited significant measles-specific cellular responses, though the CCR was lower than after routine MMR at 15 months. However, when combining serological and cellular responses, 99% of infants achieved immune conversion by 15 months. Early MMR could help reduce measles burden in infants in endemic settings without compromising subsequent immunizations."
Article snippet: Briefly, serum was prepared from a smaller, 3.5 ml, blood sample and frozen at -80 °C until use. An established measles plaque reduction neutralization test (PRNT) protocol was used to determine the 50% plaque reduction titer, and a commercial ELISA kit (Creative Diagnostics kit number DEIA359) was used to estimate the measles-specific IgG concentration after standardization using a WHO 3rd International Standard for measles antibodies. 
Figure 1. Based on randomization groups (MMR/placebo), measles-specific T cell responses are measured by ELISpot.
COA
Loading ......
